Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Duodenal Ulcer Treatment Market Size & Share 2026-2035
Report ID: GMI14360
|
Published Date: October 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Duodenal Ulcer Treatment Market
Get a free sample of this reportWhat are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.

Duodenal Ulcer Treatment Market Size
The duodenal ulcer treatment market was valued at USD 3.3 billion in 2025, is estimated to reach USD 3.47 billion in 2026, and is projected to expand at a 5.1% CAGR (2026–2035), reaching USD 5.42 billion by 2035.
Duodenal Ulcer Treatment Market Key Takeaways
Market Leader: Takeda Pharmaceutical led with over 13.5% market share in 2025.
Leading Players: Top 5 players in this market include Takeda Pharmaceutical, AstraZeneca, Eisai, Pfizer, Sun Pharma, which collectively held a market share of 41% in 2025.
The duodenal ulcer treatment market is transitioning from recovery-led demand to structurally sustained growth. Persistent infection-related disease, an expanding older patient population, and broader access to diagnosis are enlarging the treated population, while premium acid-suppression therapies are shifting revenue growth toward higher-value treatment protocols.
GMI Analyst View
Our multi-methodology triangulation across epidemiological bottom-up modeling, aggregated company GI revenue extrapolations, and GMI benchmark data indicates the global duodenal ulcer treatment market reached USD 3.2 billion in 2024. This convergence supports continuity between the market's pre-forecast trajectory and the confirmed 2025 base year.
Duodenal Ulcer Treatment Market Trends, Growth Drivers & GMI Forecast Outlook
The outlook is shaped by a widening pool of patients requiring eradication and acid-suppression therapy, alongside a commercial transition from mature generic therapies toward regimens that address resistance, treatment complexity, and the need for more consistent acid control.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
*H. pylori* remains the central clinical driver of ulcer-directed pharmaceutical demand because eradication therapy and acid suppression often must be coordinated rather than prescribed as interchangeable standalone treatments. The organism is implicated in approximately 90% of peptic ulcer disease cases [3]RedHill Biopharma Ltd. "Joint U.S. Commercialization of RedHill's Talicia® Commences." prnewswire.com. As resistance complicates conventional regimens, treatment duration, combination intensity, and the use of susceptibility-guided approaches are increasing the value of each treated episode.
Population aging broadens demand beyond infection-led care. Older patients are more likely to receive NSAIDs, manage multiple medicines simultaneously, and experience diminished mucosal resilience, increasing the need for gastroprotection and acute intervention. This shifts demand across outpatient prescriptions, hospital-administered therapies, diagnostic pathways, and follow-on maintenance care.
P-CAB adoption is changing the competitive basis of acid suppression. Faster and more consistent acid control gives vonoprazan-based protocols a differentiated role in eradication and refractory treatment settings, while their branded positioning supports a higher revenue contribution per patient than established generic PPI protocols. The category's trajectory will depend on formulary access, physician familiarity, and the pace at which clinical pathways incorporate newer regimens.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Improvements in sanitation, food handling, household conditions, and organized eradication initiatives have reduced transmission in mature healthcare markets. This limits the volume of newly infected patients in parts of North America and Europe, making revenue expansion more dependent on diagnosis, treatment completion, reimbursement, and therapeutic mix than on incidence growth alone.
Antibiotic resistance introduces a practical constraint at the point of care. Where susceptibility testing is unavailable or delayed, clinicians face a narrower set of dependable empirical options, which can slow treatment initiation and increase the likelihood of repeat courses. At the same time, resistance shifts demand toward more complex regimens and diagnostic-supported treatment pathways, creating uneven commercial effects across healthcare systems.
Safety scrutiny also constrains indefinite maintenance use of established acid-suppression therapies. Guidance favoring the lowest effective dose and shortest clinically appropriate treatment period limits the durability of some branded PPI revenue streams. The resulting pressure does not eliminate demand for acid control, but it increases the importance of differentiated therapies and evidence-based treatment selection.
GMI Analyst View
We expect market growth to separate into two distinct commercial tracks: premium protocols centered on differentiated acid suppression and a high-volume generic base serving broad access needs. The balance between those tracks will be determined by reimbursement design, diagnostic capability, and the ability of providers to adapt eradication regimens to local resistance patterns.
Duodenal Ulcer Treatment Market Segment Analysis
By Treatment Type
Pharmacological Treatment
Pharmacological treatment accounted for 91.0% of market revenue in 2025 and is projected to reach USD 4.94 billion by 2035. The duodenal ulcer treatment market remains anchored in drug-based management because acid suppression and eradication therapy address the majority of cases across outpatient, hospital, and homecare settings. Within this category, treatment complexity is increasing as clinicians balance resistance-aware antibiotic selection with demand for more durable acid control.
Proton Pump Inhibitors
Proton pump inhibitors represented 46.0% of market revenue in 2025 and are expected to reach USD 2.22 billion by 2035. Their installed clinical base, generic availability, and broad familiarity preserve substantial volume; however, pricing pressure and the migration of selected patients toward P-CABs are gradually changing the class's revenue mix.
H2 Antagonists
H2 antagonists are forecast to generate USD 379 million by 2035 and expand at a 0.5% CAGR (2026–2035). The class retains relevance in milder or episodic acid-related use, but its role is increasingly limited where sustained acid suppression or eradication support is required.
Antibiotics
Antibiotics generated USD 858 million in 2025 and are projected to grow at a 7.6% CAGR (2026–2035). Resistance to traditional regimens is driving a move toward longer, more complex, and more closely managed eradication protocols, making antibiotic selection a larger determinant of treatment costs and clinical outcomes.
Other Drug Classes
Other drug classes generated USD 264 million in 2025 and are expected to reach USD 679 million by 2035. This category includes P-CABs, bismuth compounds, cytoprotective agents, and antacids, with P-CABs supplying the principal source of value expansion as differentiated products gain wider clinical acceptance.
Surgery
Surgery accounted for 9.0% of market revenue in 2025 and is forecast to reach USD 489 million by 2035. Demand is concentrated in refractory disease and severe complications, while therapeutic endoscopy is shifting more appropriate cases toward less invasive management and expanding the importance of specialized procedural capacity.
By Age Group
Adults Aged 18 to 64
Adults aged 18 to 64 generated USD 2.11 billion in 2025 and are projected to expand at a 4.2% CAGR (2026–2035). Infection exposure, NSAID use, and lifestyle-associated risk factors sustain a large treatment base, although demographic momentum is increasingly moving toward older patients with more complex medication profiles.
Geriatric Patients
Geriatric patients represented 36% of market revenue in 2025 and are projected to reach USD 2.23 billion by 2035. Greater NSAID exposure, polypharmacy, and age-related loss of mucosal protection increase the likelihood of complicated presentations and support demand across both acute-care and maintenance-treatment settings.
By End Use
Hospitals and Clinics
Hospitals and clinics accounted for 58% of market revenue in 2025 and are forecast to reach USD 3.15 billion by 2035. Their leading position reflects responsibility for acute bleeding management, diagnostic endoscopy, biopsy-based testing, and the delivery of intravenous and procedure-supported care for complex cases.
Homecare Settings
Homecare settings represented 22% of market revenue in 2025 and are projected to reach USD 1.19 billion by 2035. Digital prescribing, telemedicine, and outpatient management are reducing barriers between symptom recognition and treatment initiation, particularly for oral eradication and maintenance protocols.
Ambulatory Surgical Centers
Ambulatory surgical centers held a 12% market share in 2025 and are expected to generate USD 651 million by 2035. Their role is expanding as diagnostic and therapeutic endoscopy moves into lower-cost, higher-throughput outpatient environments where appropriate clinical pathways and reimbursement support the shift.
Other End-Use Channels
Other end-use channels accounted for 8% of market revenue in 2025 and are forecast to reach USD 434 million by 2035. Retail and online pharmacies are gaining relevance through generic PPI dispensing, over-the-counter therapies, and community access to maintenance prescriptions.
GMI Analyst View
We see the most consequential segment shift occurring within pharmacological care rather than away from it. Treatment selection is becoming more clinically differentiated, with resistance-aware eradication regimens, premium acid suppression, and care settings that lower access friction reshaping the mix of revenue across the market.
Duodenal Ulcer Treatment Market Regional Analysis
North America Duodenal Ulcer Treatment Market Analysis
North America accounted for 38% of global revenue in 2025 and is forecast to reach USD 2.06 billion by 2035. The duodenal ulcer treatment market in the region benefits from high pharmaceutical spending, established branded-drug coverage, and early commercialization of P-CAB-based care, although mature infection trends make therapeutic mix and treatment penetration critical to further expansion.
United States
The United States generated USD 1.12 billion in 2025 and is projected to reach USD 1.85 billion by 2035. The market's premium profile is supported by the rollout of vonoprazan-based eradication regimens, concentrated specialist care, payer capacity for branded therapies, and increasing use of resistance-adaptive treatment options.
Canada
Canada generated USD 132 million in 2025 and is forecast to reach USD 216 million by 2035. Population aging and primary-care expansion of testing and eradication pathways support demand, particularly where prevention-oriented management is directed toward higher-prevalence patient populations.
Europe Duodenal Ulcer Treatment Market Analysis
Europe represented 26% of global revenue in 2025 and is expected to reach USD 1.41 billion by 2035. The duodenal ulcer treatment market across Europe is supported by advanced clinical infrastructure and established treatment guidelines, while reference pricing and health technology assessment practices moderate the pace of premium-therapy uptake.
Germany
Germany generated USD 163 million in 2025 and is forecast to reach USD 268 million by 2035. Broad insurance coverage, specialist density, and adherence to susceptibility-informed eradication approaches support comparatively complex treatment pathways and reliable patient access.
United Kingdom
The United Kingdom generated USD 138 million in 2025 and is expected to reach USD 227 million by 2035. Structured primary-care testing and treatment pathways underpin volume, while formulary discipline and generic utilization temper the revenue contribution of branded acid-suppression products.
France
France generated USD 129 million in 2025 and is forecast to reach USD 212 million by 2035. Favorable reimbursement for established gastroenterology products and the role of private specialist care support continued use of premium formulations alongside generic therapies.
Asia Pacific Duodenal Ulcer Treatment Market Analysis
Asia Pacific accounted for 25% of global revenue in 2025 and is projected to grow at a 5.7% CAGR (2026–2035). The duodenal ulcer treatment market in Asia Pacific combines high infection burden, expanding healthcare access, and a diverse commercial environment in which mature P-CAB adoption in selected countries coexists with broad-based generic expansion.
China
China generated USD 264 million in 2025 and is forecast to reach USD 438 million by 2035. Procurement-driven generic pricing expands treatment access, while screening initiatives, hospital-based specialist care, and growing acceptance of premium therapies sustain a layered demand profile.
Japan
Japan generated USD 215 million in 2025 and is expected to reach USD 354 million by 2035. Its established experience with vonoprazan, broad reimbursement for clinically confirmed eradication treatment, and an older patient population reinforce the country's role as a reference market for P-CAB-led care.
India
India generated USD 153 million in 2025 and is projected to expand at a 6.2% CAGR (2026–2035). Growth is supported by improving diagnostic capacity, rising availability of locally manufactured therapies, and an expanding need for accessible acid-suppression and eradication treatment across urban healthcare networks.
South Korea
South Korea generated USD 99 million in 2025 and is forecast to reach USD 164 million by 2035. The country's advanced acid-suppression market and adoption of multiple domestically developed P-CABs position it as an important center for therapeutic innovation and prescriber experience.
Latin America Duodenal Ulcer Treatment Market Analysis
Latin America accounted for 6% of global revenue in 2025 and is projected to reach USD 326 million by 2035. High underlying infection burden and improving access to diagnosis are widening the addressable treatment pool, while price-sensitive payer structures maintain a strong role for generic therapies.
Brazil
Brazil generated USD 88 million in 2025 and is expected to reach USD 145 million by 2035. Expanding private coverage, public gastroenterology capacity, and growing recognition of infection-related gastrointestinal risk are supporting more systematic testing and treatment in urban care networks.
Mexico
Mexico generated USD 61 million in 2025 and is forecast to reach USD 100 million by 2035. Growth is linked to wider community-pharmacy dispensing, improving access to diagnostic endoscopy, and increasing use of specialist care within the private health sector.
Middle East and Africa Duodenal Ulcer Treatment Market Analysis
The Middle East and Africa market generated USD 165 million in 2025 and is projected to reach USD 270 million by 2035. Healthcare infrastructure investment, higher demand for gastroprotective therapies in some labor-intensive economies, and improving diagnostic capacity are strengthening the region's treatment base.
Saudi Arabia
Saudi Arabia generated USD 50 million in 2025 and is forecast to reach USD 82 million by 2035. Investment in primary and specialist care is supporting broader screening and treatment capability, while private providers are expanding access to branded acid-suppression therapies.
United Arab Emirates
The United Arab Emirates generated USD 38 million in 2025 and is expected to reach USD 63 million by 2035. Retail pharmacy development, a large expatriate population, and evolving chronic-disease management initiatives are supporting sustained demand for accessible gastrointestinal care.
South Africa
South Africa generated USD 30 million in 2025 and is forecast to reach USD 49 million by 2035. The coexistence of public generic dispensing and private-sector branded treatment creates a segmented growth profile, with access and payer coverage shaping product mix.
GMI Analyst View
We expect regional opportunity to be defined less by a single global treatment model than by each market's ability to combine diagnosis, reimbursement, and regimen sophistication. Mature markets will monetize innovation through premiumization, while high-growth markets will increasingly determine volume through greater access to standard and emerging therapies.
Duodenal Ulcer Treatment Market Share & Competitive Landscape
The duodenal ulcer treatment market share is distributed across branded gastrointestinal specialists, diversified pharmaceutical companies, and generic manufacturers with strong regional positions. Competitive intensity is increasing as P-CAB commercialization challenges the long-standing role of PPIs, while antibiotic resistance and formulary requirements make clinical evidence, manufacturing reach, and channel execution more consequential.
Takeda Pharmaceutical held a 13.5% market share in 2025, supported by its vonoprazan franchise across Japan and broader Asia Pacific markets, as well as U.S. commercialization through a licensing structure. Its early P-CAB position and depth of clinical experience provide a meaningful advantage as prescribers adopt newer eradication and acid-suppression protocols.
AstraZeneca accounted for 9.5% of market revenue in 2025. Its established esomeprazole franchise retains value in markets where branded gastrointestinal products maintain reimbursement support or formulary standing, though generic competition and the absence of a comparable P-CAB platform create longer-term portfolio pressure.
Eisai represented 6.5% of market revenue in 2025. The company's rabeprazole presence remains relevant in Japan and Asia Pacific, but its competitive position is increasingly exposed to the continued transition from established PPIs toward P-CAB-based treatment strategies.
Generic manufacturers remain central to market access, particularly in Asia Pacific, Latin America, the Middle East, and Africa. Companies with cost-efficient manufacturing, local regulatory expertise, and broad pharmacy distribution are positioned to benefit from rising treatment penetration, while branded competitors must demonstrate differentiation through efficacy, regimen convenience, and specialist adoption.
Recent Industry Developments
Daewoong Pharmaceutical reported in September 2026 that Fexuclue, its fexuprazan hydrochloride P-CAB, achieved a 92% *H. pylori* eradication rate among patients completing a concomitant three-antibiotic regimen in a clinical study. The results provide additional evidence for the use of differentiated acid suppression in resistance-complicated eradication settings [4]Seoul Economic Daily. "Daewoong's Fexuclue With Three Antibiotics Clears H. pylori in 92% of Patients." sedaily.com.
RedHill Biopharma Ltd. and Cumberland Pharmaceuticals Inc. began joint U.S. commercialization of Talicia for *H. pylori* infection treatment in February 2026. The arrangement extends Talicia's commercial reach through a dedicated gastroenterology sales infrastructure and supports broader deployment of a rifabutin-based regimen [3]RedHill Biopharma Ltd. "Joint U.S. Commercialization of RedHill's Talicia® Commences." prnewswire.com.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →